Results 151 to 160 of about 476,712 (311)

Advancing back to the Middle Ages: the barbers of Saxmundham. [PDF]

Br J Gen Pract
Havard J.
europepmc   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Des Basilius aus Achrida, Erzbischofs von Thessalonich, bisher unedierte Dialoge. Josef SchmidtRegula Antiqua Fratrum et Sororum seu Tertii Ordinis Sancti Francisci. Paul SabatierThe Development of Doctrine from the Early Middle Ages to the Reformation. John S. BanksThe Reformation Dawn. F. V. N. PainterLa controverse de l'apostolicité des églises de France au XIXe siècle. A. HoutinThe Crime of Christendom; Or, The Eastern Question from Its Origin to the Present Time. Daniel Seelye Gregory [PDF]

, 1902
J. W. Moncrief
openalex   +1 more source

Evolution of the Asian summer monsoon and regional karst ecological environment since the middle ages in Southwest China. [PDF]

Sci Rep
Wang CY, Li JY, Chen CJ, Zhang J, Wu Y, Cheng H, Shen CC, Li TY.   +7 more
europepmc   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Ibn al-Jazzar (al-Gizar): A Renowned Tunisian Physician in General Medicine, Women's Diseases, and Pediatrics During the Middle Ages. [PDF]

Cureus
Zridi S, Dghim I, Jellad A.
europepmc   +1 more source

Between belief and fear - Reinterpreting prone burials during the Middle Ages and early modern period in German-speaking Europe. [PDF]

PLoS One, 2020
Alterauge A, Meier T, Jungklaus B, Milella M, Lösch S.   +4 more
europepmc   +1 more source

Tumor‐agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell‐free DNA fragmentomics

Molecular Oncology, EarlyView.
We evaluated circulating tumor DNA (ctDNA) detection in advanced pancreatic cancer using DNA methylation, cell‐free DNA fragment lengths, and 5′ end motifs. Machine learning models were trained to estimate ctDNA levels from each feature and their combination.
Morten Lapin, Kjersti Tjensvoll, Karin Hestnes Edland, Satu Oltedal, Herish Garresori, Bjørnar Gilje, Saga Ekedal, Trygve Eftestøl, Jan Terje Kvaløy, Filip Janku, Oddmund Nordgård   +10 more
wiley   +1 more source

Arabian society in the middle ages

, 1883

openalex   +2 more sources

Microscopical Section from the Epiglottis of a Middle-aged Male Patient, with Supposed Tuberculosis [PDF]

, 1924
James Dundas‐Grant
openalex   +1 more source